Dual GLP-1/Glucagon Agonist For NASH

A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, leading to fibrosis or eventually liver cancer. Because Pemvidutide acts across these multiple pathways, it may be able to correct the metabolic dysfunction at the heart of NASH as demonstrated in one of the best preclinical models of the disease.